Abstract
Up to 30% of patients with advanced germ cell tumors will fail induction chemotherapy or will relapse. New agents with activity in this still potentially curable subgroup of patients are needed. Edatrexate (10-ethyl, 10-deaza-aminopterin) is a methotrexate analogue that has preclinical and clinical activity in breast, lung, and head and neck cancers, as well as in non-Hodgkin's lymphomas. A phase II trial of edatrexate in relapsed or refractory malignant germ cell tumors was conducted by the Southwest Oncology Group (SWOG). Twenty-five patients were enrolled in the trial. Edatrexate was administered intravenously at a dose of 80 mg/m2 weekly for four weeks followed by a one-week rest period. The treatment course was repeated every five weeks. Among the 23 patients evaluable for response, there were no objective responses with all patients developing progressive disease. Thirteen patients (56%) developed Grade 3–4 toxicities, predominantly stomatitis and malaise/fatigue/lethargy. One patient developed Grade 4 anemia while another developed grade 4 anemia and thrombocytopenia. No patients discontinued treatment due to toxicity nor were there any toxic deaths. Edatrexate administered in this dose and schedule has no antitumor activity and has substantial toxicity in patients with relapsed or refractory germ cell tumors.
Similar content being viewed by others
References
Einhorn L: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
Nichols CR, Saxman S: Primary salvage treatment of recurrent germ cell tumors: Experience at Indiana University. Semin Oncol 25(2):210-214, 1998
Sirotnak FM, DeGraw J, Moccio DM et al.: New folate analogs of the 10-deaza-aminopterin series: Basis for structural design and biochemical pharmacological properties. Cancer Chemother Pharmacol 12:18-25, 1984
Smith DB, Rustin GJ, Hitchins R et al.: Single agent activity of methotrexate in advanced non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol 24(11):1779-1781, 1988
Grant SC, Kris MG, Young CW, Sirotnak FM: Edatrexate, an antifolate with antitumor activity: A review. Cancer Invest 11(1):36-45, 1993
Wertheim M, Kris M, Gralla R et al.: Phase I clinical pharmacologic study of 10-ethyl-10-deaza-aminopterin (edatrexate). Proc Am Assoc Cancer Res 26:356, 1985
Pazdur R, Moore DF, Bready B et al.: Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma. Ann Oncol 5(7):646-648, 1994
Wiesenfeld M, Jett R, Su JQ et al.: Phase II trial of edatrexate in small cell lung cancer. Cancer 73(4):1189-1193, 1994
Moore DF, Pazdur R, Abbruzzese JL et al.: Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol 5(3):286-287, 1994
Clamon GH, Riggs CE, Dreicer R, Hohl RJ: Phase II trial of edatrexate in patients with metastatic colorectal cancer. Invest New Drugs 13(4):359-361, 1996
Broun ER, Iseminger KA, Rose PG et al.: A phase II trial of edatrexate in previously treated squamous cell cervical cancer: A Gynecologic Oncology Group study. Am J Clin Oncol 20(1):78-80, 1997
Broun ET, Iseminger KA, Bookman M: A Phase II trial of edatrexate in previously treated ovarian cancer: A Gynecologic Oncology Group study. Am J Clin Oncol 18(2):164-166, 1995
Liebertz C, Scher HI, Kelly WK et al.: Phase II trial of edatrexate in patients with adenocarcinoma of prostate using prostate-specific antigen as the clinical endpoint. Proc Am Assoc Cancer Res 34:A1211, 1993
Dreicer R, Propert KJ, Kuzel T et al.: A phase II trial of edatrexate in patients with advanced renal cell carcinoma: An Eastern Cooperative Oncology Group study. Am J Clin Oncol 20(3):251-253, 1997
Verma S, Quirt IC, Eisenhauer EA et al.: A phase II study of weekly edatrexate in metastatic melanoma: A National Cancer Institute of Canada Clinical Trials Group study. Ann Oncol 4(3):254-255, 1993
Schornagel JH, Verweij J, de Mulder PH et al.: Randomized phase III trial of edatrexate versusmethotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol 13(7):1649-1655, 1995
Souhami R, Rudd RM, Spiro RG et al.: Phase II study of edatrexate in stage III and IV non-small cell lung cancer. Cancer Chemother Pharmacol 30(6):465-468, 1992
Schornagel JH, van der Vegt S, Verweij J et al.: Phase II study of edatrexate in chemotherapy-naïve patients with metastatic breast cancer. Ann Oncol 3(7):549-552, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meyers, F.J., Lew, D., Lara, P.N. et al. Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124). Invest New Drugs 16, 347–351 (1998). https://doi.org/10.1023/A:1006128024879
Issue Date:
DOI: https://doi.org/10.1023/A:1006128024879